Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.

Chan, Andrew; Silván, Carlos Vila (2022). Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegenerative disease management, 12(3), pp. 141-154. Future Medicine 10.2217/nmt-2022-0002

[img]
Preview
Text
nmt-2022-0002.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Effective symptomatic management of multiple sclerosis (MS) spasticity remains an unmet need for many patients. The second-line option nabiximols is the most widely investigated of the noninvasive antispasticity medications in this patient population. Clinical evidence accumulated with nabiximols since it was first approved in Europe in 2010 suggests that about 40% of initial responders (i.e., those with ≥20% improvement in their baseline 0-10 Numerical Rating Scale score) may expect to achieve clinically meaningful (≥30% Numerical Rating Scale response) and durable symptomatic improvement in MS spasticity. During 10 years' routine use of nabiximols, no new safety signals have emerged. Nabiximols-associated improvement in MS spasticity-related symptoms such as pain and sleep disruption suggests a need to track possible therapeutic effects beyond muscle tone control.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Chan, Andrew Hao-Kuang

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1758-2024

Publisher:

Future Medicine

Language:

English

Submitter:

Pubmed Import

Date Deposited:

05 Apr 2022 09:55

Last Modified:

05 Dec 2022 16:18

Publisher DOI:

10.2217/nmt-2022-0002

PubMed ID:

35377770

Uncontrolled Keywords:

multiple sclerosis spasticity nabiximols real-world evidence spasticity-plus syndrome

BORIS DOI:

10.48350/168999

URI:

https://boris.unibe.ch/id/eprint/168999

Actions (login required)

Edit item Edit item
Provide Feedback